German medical device company B. Braun Medical announced that the FDA has issued Emergency Use Authorization (EUA) of several of the company’s infusion pumps for “tracheal delivery of continuous nebulized medications into a nebulizer to treat patients of all ages with or suspected of having the Coronavirus Disease 2019 (COVID-19) and to decrease the exposure of healthcare providers (HCP) to such patients during the COVID-19 pandemic.” The company submitted the EUA request on April 8, 2020.
B. Braun Chief Medical Officer and Senior VP, Scientific Affairs, Wes Cetnarowski commented, “This authorization allows for an alternative method to administer continuous nebulized medications to patients who are critically ill with COVID-19, many of whom are on ventilation. As hospitals struggle to cope with the surge of patients suffering from this deadly disease, this action provides another tool for healthcare professionals on the front line to treat some of the most serious cases while helping to protect clinicians by reducing their exposure to infected patients.”
Chairman and CEO Jean-Claude Dubacher added, “We applaud this decisive action taken by the FDA to help some of the most seriously ill COVID-19 patients. The rapid review and authorization of this and other COVID-19 countermeasures demonstrate the agency’s commitment to ensure that healthcare providers have the medical devices and treatments they need to fight this disease.”
Read the B. Braun press release.
